Literature DB >> 30829618

Quantitative Sensory Testing (QST) in Drug-Naïve Patients with Parkinson's Disease.

Odette Fründt1, Wiebke Grashorn1, Carsten Buhmann1, Katarina Forkmann2, Tina Mainka3, Ulrike Bingel2,4, Katharina Schmidt2.   

Abstract

BACKGROUND: Pain is highly prevalent in patients with Parkinson's disease (PD), but underlying pathophysiological mechanisms are largely unclear. Alterations in somatosensory processing might contribute to sensory abnormalities in PD.
OBJECTIVE: This study investigated sensory processing in PD patients.
METHODS: We used the standardized "Quantitative Sensory Testing" (QST) protocol (German Research Network on Neuropathic Pain) to investigate 13 somatosensory parameters in 19 PD patients naïve to dopaminergic medication and 19 healthy controls matched for age, gender, and handedness. We tested for differences in sensory parameters between i) drug-naïve PD patients and healthy controls, ii) patients' more and less affected body side, and iii) for an association of somatosensory parameters with disease-specific factors.
RESULTS: We did not observe any significant group differences in somatosensory parameters between PD patients and healthy subjects. In PD patients, QST mean z-scores did not differ between the predominantly and the less affected body side, PD patients with and without PD-specific chronic pain or between different PD subtypes. Age, but not PD disease severity, was associated with a greater loss of function in thermal and mechanical detection thresholds.
CONCLUSIONS: Somatosensory processing, as assessed with the well-established QST protocol, was normal in drug-naïve PD patients. Thus, somatosensory abnormalities previously reported in medicated PD patients might rather be a result of dopaminergic medication, or may occur later in the course of the disease or with increasing age.

Entities:  

Keywords:  Parkinson’s disease; QST; drug-naïve; quantitative sensory testing

Mesh:

Year:  2019        PMID: 30829618     DOI: 10.3233/JPD-181513

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  5 in total

Review 1.  Towards optimising experimental quantification of persistent pain in Parkinson's disease using psychophysical testing.

Authors:  Rory V Smith; Patrick Wilkins; Kirsty Bannister; Tatum M Cummins
Journal:  NPJ Parkinsons Dis       Date:  2021-03-17

2.  Sympathetic and sensory nerve fiber function in multiple system atrophy and idiopathic Parkinson's disease.

Authors:  Christian Geber; Frank Birklein; Heidrun H Krämer; Cora Rebhorn
Journal:  J Neurol       Date:  2021-03-13       Impact factor: 4.849

3.  Altered Intra- and Inter-Network Connectivity in Drug-Naïve Patients With Early Parkinson's Disease.

Authors:  Weiqi Zeng; Wenliang Fan; Xiangchuang Kong; Xiaoming Liu; Ling Liu; Ziqin Cao; Xiaoqian Zhang; Xiaoman Yang; Chi Cheng; Yi Wu; Yu Xu; Xuebing Cao; Yan Xu
Journal:  Front Aging Neurosci       Date:  2022-02-14       Impact factor: 5.750

4.  Corneal confocal microscopy differentiates patients with Parkinson's disease with and without autonomic involvement.

Authors:  Ning-Ning Che; Shuai Chen; Qiu-Huan Jiang; Si-Yuan Chen; Zhen-Xiang Zhao; Xue Li; Rayaz A Malik; Jian-Jun Ma; Hong-Qi Yang
Journal:  NPJ Parkinsons Dis       Date:  2022-09-09

5.  Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease.

Authors:  Timothy Lawn; Yahyah Aman; Katarina Rukavina; George Sideris-Lampretsas; Matthew Howard; Clive Ballard; Kallol Ray Chaudhuri; Marzia Malcangio
Journal:  Pain       Date:  2021-04-01       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.